Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GTHX

G1 Therapeutics Inc

Jul 26 • 04:00PM ET

3.91

Dollar change -0.04
Percentage change -1.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI IWO VXF VTWO IWC FESM GSSC RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	18.23%	Shs Outstand	51.93M	Perf Week	7.71%
Market Cap	204.41M	Forward P/E	-	EPS next Y	-0.16	Insider Trans	-1.32%	Shs Float	42.75M	Perf Month	73.78%
Income	-30.59M	PEG	-	EPS next Q	-0.17	Inst Own	27.59%	Short Float	16.46%	Perf Quarter	1.30%
Sales	84.04M	P/S	2.43	EPS this Y	43.95%	Inst Trans	12.28%	Short Ratio	4.43	Perf Half Y	1.82%
Book/sh	0.53	P/B	7.36	EPS next Y	68.49%	ROA	-23.18%	Short Interest	7.03M	Perf Year	64.29%
Cash/sh	1.25	P/C	3.13	EPS next 5Y	-	ROE	-84.13%	52W Range	1.08 - 6.14	Perf YTD	28.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.38%	ROI	-44.41%	52W High	-36.32%	Beta	1.43
Dividend TTM	-	Quick Ratio	2.55	Sales past 5Y	18.67%	Gross Margin	91.89%	52W Low	262.04%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	2.94	EPS Y/Y TTM	78.79%	Oper. Margin	-27.16%	RSI (14)	71.67	Volatility	7.42% 8.21%
Employees	100	Debt/Eq	1.70	Sales Y/Y TTM	46.55%	Profit Margin	-36.40%	Recom	1.71	Target Price	4.10
Option/Short	Yes / Yes	LT Debt/Eq	1.48	EPS Q/Q	63.34%	Payout	-	Rel Volume	0.31	Prev Close	3.95
Sales Surprise	-4.83%	EPS Surprise	-0.96%	Sales Q/Q	11.82%	Earnings	Aug 08 BMO	Avg Volume	1.59M	Price	3.91
SMA20	27.22%	SMA50	20.65%	SMA200	25.66%	Trades		Volume	492,235	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Upgrade	JP Morgan	Underweight → Neutral	$7 → $10
Jan-03-23	Reiterated	Needham	Buy	$32 → $31
Nov-04-21	Downgrade	JP Morgan	Neutral → Underweight	$20 → $19
Oct-15-21	Resumed	BTIG Research	Buy	$51
Sep-30-21	Downgrade	JP Morgan	Overweight → Neutral	$24 → $20
Nov-17-20	Downgrade	Raymond James	Strong Buy → Outperform
Jun-26-20	Initiated	ROTH Capital	Buy	$55
Jan-21-20	Reiterated	H.C. Wainwright	Buy	$72 → $82
Aug-08-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-07-19	Initiated	B. Riley FBR	Buy	$55
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-20-18	Initiated	Raymond James	Strong Buy
Nov-08-18	Reiterated	Needham	Buy	$76 → $74
Sep-10-18	Resumed	BTIG Research	Buy	$80
May-29-18	Initiated	H.C. Wainwright	Buy	$61
May-18-18	Reiterated	Needham	Buy	$42 → $60

Show Previous Ratings

Jul-25-24 11:15AM	G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire) +5.90%
Jul-15-24 02:00PM	G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025 (InvestorPlace)
Jul-10-24 06:40AM	Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble (InvestorPlace)
Jul-01-24 08:00AM	G1 Therapeutics Added to the Russell 2000 and 3000 Indexes (GlobeNewswire) +8.33%
Jun-25-24 06:12AM	G1 Therapeutics discontinue COSELA in TNBC following Phase III flop (Clinical Trials Arena)
10:52AM	Loading…
Jun-24-24 10:52AM	Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears (InvestorPlace) -10.48%
10:31AM	Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts (InvestorPlace)
08:23AM	Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? (InvestorPlace)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:30AM	G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) (GlobeNewswire)
Jun-05-24 07:00AM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 06:30AM	Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) (GlobeNewswire) -16.87%
May-23-24 05:06PM	G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting (GlobeNewswire)
May-22-24 10:00AM	G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit (GlobeNewswire)
06:30AM	G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses (GlobeNewswire)
10:43AM	Loading…
May-02-24 10:43AM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.51%
03:09AM	G1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-01-24 11:04PM	Q1 2024 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.55%
05:50PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:33AM	Pepper Bio spices up pipeline with $135M deal for G1 Therapeutics' CDK4/6 inhibitor (FierceBiotech.com)
07:54AM	G1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue Projections (GuruFocus.com)
07:40AM	G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
06:25AM	G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib (GlobeNewswire)
Apr-17-24 09:00AM	G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 (GlobeNewswire)
Apr-11-24 09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
Apr-04-24 10:30AM	G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 04:20PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.32%
Mar-01-24 04:20PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.35%
Feb-29-24 10:21AM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:09PM	Loading…
Feb-28-24 11:09PM	Q4 2023 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +38.75%
07:40AM	G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:51AM	G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 (GuruFocus.com)
06:30AM	G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-27-24 08:30AM	G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-15-24 08:30AM	G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024 (GlobeNewswire)
Feb-13-24 08:15AM	Why Is G1 Therapeutics (GTHX) Stock Down 45% Today? (InvestorPlace) -53.12%
Feb-12-24 04:05PM	G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee (GlobeNewswire)
Jan-08-24 06:45AM	G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +17.87%
Jan-03-24 05:02PM	Insider Sell: President and CEO Bailey John E. (Jack) Jr. Sells 32,983 Shares of G1 Therapeutics Inc (GuruFocus.com)
09:00AM	G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 04:51PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-13-23 11:05PM	Insider Sell Alert: Chief Medical Officer Rajesh Malik Offloads Shares of G1 Therapeutics Inc (GuruFocus.com) -35.39%
Dec-05-23 09:26AM	G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy (GlobeNewswire) -8.00%
Dec-01-23 04:27PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.38%
Nov-29-23 08:37PM	G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire) +10.59%
Nov-02-23 09:46AM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript (Insider Monkey) +21.64%
Nov-01-23 11:49PM	Q3 2023 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -18.79%
09:45AM	G1 Therapeutics Inc (GTHX) Reports Q3 2023 Earnings: $12.3 Million in Total Revenue (GuruFocus.com)
06:30AM	G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Oct-27-23 07:00AM	Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (GlobeNewswire)
Oct-26-23 10:02AM	Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +6.62%
Oct-25-23 10:01AM	Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-18-23 08:00AM	G1 Therapeutics' COSELA (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO) (GlobeNewswire)
07:30AM	G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023 (GlobeNewswire)
Oct-16-23 09:00AM	G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium (GlobeNewswire) +5.26%
Sep-18-23 07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-05-23 11:00AM	G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 04:15PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 07:45AM	G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Jul-31-23 02:30PM	G1 Therapeutics to Participate in Two August Investor Conferences (GlobeNewswire)
08:30AM	New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (GlobeNewswire)
Jul-27-23 09:42AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutions (Simply Wall St.)
Jul-26-23 09:00AM	G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023 (GlobeNewswire)
Jul-06-23 04:15PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-23 09:17AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Path To Profitability (Simply Wall St.)
07:13AM	Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy (GlobeNewswire)
Jun-01-23 04:40PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-22-23 04:45PM	G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel (GlobeNewswire)
May-16-23 07:30AM	New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer (GlobeNewswire) -7.19%
May-10-23 07:31AM	New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC) (GlobeNewswire)
May-08-23 06:02AM	Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX) (Simply Wall St.) -5.19%
May-05-23 06:12AM	G1 Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-03-23 02:20PM	RTP drug developer adds $30M to extend cash runway (American City Business Journals)
07:45AM	G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-01-23 05:00PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.32%
Apr-26-23 12:45PM	G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 (GlobeNewswire)
Apr-18-23 10:16AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shares Lagging The Industry But So Is The Business (Simply Wall St.)
Apr-12-23 12:00PM	G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Apr-11-23 12:30PM	G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 09:55PM	G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2022 Earnings Call Transcript (Insider Monkey)
12:01AM	Q4 2022 G1 Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-01-23 07:55AM	G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:30AM	G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire)
Feb-28-23 02:10PM	G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-22-23 10:00AM	G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023 (GlobeNewswire)
Feb-17-23 07:40AM	G1 Therapeutics, Inc.'s (NASDAQ:GTHX) latest 46% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Feb-16-23 10:01AM	Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-15-23 10:00AM	G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) +6.07%
Feb-13-23 01:33PM	G1 Therapeutics stock plummets 50% after trial cut short for cancer drug (American City Business Journals) -53.16%
08:03AM	G1 to discontinue study of colorectal cancer treatment (MarketWatch)
07:00AM	G1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo Arm (Benzinga)
06:00AM	G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) (GlobeNewswire)
Feb-09-23 08:00AM	First Prescription for COSELA® (trilaciclib) Issued in China (PR Newswire)
Feb-01-23 04:46PM	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-23 07:00AM	G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference (GlobeNewswire)
Jan-09-23 06:30AM	G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib (GlobeNewswire)
Jan-04-23 11:01AM	G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial (Benzinga)

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bailey John E. (Jack) Jr.	President and CEO	Jul 05 '24	Sale	2.51	7,662	19,214	549,674	Jul 08 05:53 PM
Avagliano Mark	Chief Business Officer	Jul 05 '24	Sale	2.51	2,638	6,615	242,045	Jul 08 05:55 PM
MURDOCK TERRY L	Chief Operating Officer	Jul 05 '24	Sale	2.51	2,475	6,207	128,012	Jul 08 05:58 PM
Malik Rajesh	Chief Medical Officer	Jul 05 '24	Sale	2.51	2,475	6,207	159,312	Jul 08 05:57 PM
Perry Andrew	Chief Commercial Officer	Jul 05 '24	Sale	2.51	1,337	3,353	112,614	Jul 08 05:59 PM
Umstead John W. V	Chief Financial Officer	Jul 05 '24	Sale	2.51	527	1,322	187,718	Jul 08 05:54 PM
Thomas Monica R.	Chief Legal & People Officer	May 23 '24	Sale	4.27	5,826	24,864	109,825	May 24 04:15 PM
Bailey John E. (Jack) Jr.	President and CEO	May 13 '24	Sale	4.79	37,258	178,421	452,336	May 15 04:06 PM
MURDOCK TERRY L	Chief Operating Officer	May 13 '24	Sale	4.79	8,151	39,034	95,487	May 15 04:10 PM
Umstead John W. V	Chief Financial Officer	May 13 '24	Sale	4.79	8,151	39,034	153,245	May 15 04:11 PM
Malik Rajesh	Chief Medical Officer	May 13 '24	Sale	4.79	8,151	39,034	161,787	May 15 04:08 PM
Avagliano Mark	Chief Business Officer	May 13 '24	Sale	4.79	8,151	39,034	209,683	May 15 04:07 PM
Umstead John W. V	Chief Financial Officer	Mar 18 '24	Sale	3.02	6,547	19,752	123,896	Mar 20 04:32 PM
Malik Rajesh	Chief Medical Officer	Feb 12 '24	Option Exercise	0.30	28,600	8,580	198,538	Feb 13 06:14 PM
Malik Rajesh	Chief Medical Officer	Feb 12 '24	Sale	4.62	28,600	132,143	169,938	Feb 13 06:14 PM
MURDOCK TERRY L	Chief Operating Officer	Jan 04 '24	Sale	2.94	721	2,121	103,638	Jan 08 06:00 AM
Avagliano Mark	Chief Business Officer	Jan 04 '24	Sale	2.94	721	2,121	117,834	Jan 08 06:02 AM
Malik Rajesh	Chief Medical Officer	Jan 04 '24	Sale	2.94	721	2,121	169,938	Jan 08 06:03 AM
Umstead John W. V	Chief Financial Officer	Jan 04 '24	Sale	2.94	111	327	130,443	Jan 08 06:04 AM
Bailey John E. (Jack) Jr.	President and CEO	Jan 03 '24	Sale	3.12	11,686	36,447	489,594	Jan 08 06:02 AM
Avagliano Mark	Chief Business Officer	Jan 03 '24	Sale	3.12	3,360	10,480	118,555	Jan 08 06:02 AM
MURDOCK TERRY L	Chief Operating Officer	Jan 03 '24	Sale	3.12	3,019	9,416	104,359	Jan 08 06:00 AM
Malik Rajesh	Chief Medical Officer	Jan 03 '24	Sale	3.12	3,019	9,416	170,659	Jan 08 06:03 AM
Perry Andrew	Chief Commercial Officer	Jan 03 '24	Sale	3.12	2,413	7,526	87,102	Jan 08 06:03 AM
Umstead John W. V	Chief Financial Officer	Jan 03 '24	Sale	3.12	632	1,971	130,554	Jan 08 06:04 AM
Bailey John E. (Jack) Jr.	President and CEO	Jan 02 '24	Sale	3.27	32,983	108,006	400,580	Jan 02 07:44 PM
Malik Rajesh	Chief Medical Officer	Dec 11 '23	Option Exercise	0.36	33,839	12,081	157,817	Dec 13 04:45 PM
Malik Rajesh	Chief Medical Officer	Dec 11 '23	Sale	3.41	33,839	115,522	136,378	Dec 13 04:45 PM
Velleca Mark A.	Director	Aug 08 '23	Option Exercise	0.39	60,000	23,156	173,286	Aug 10 04:11 PM
Velleca Mark A.	Director	Aug 08 '23	Sale	2.00	60,000	119,974	116,000	Aug 10 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GTHX

G1 Therapeutics Inc

Upgrade your FINVIZ experience